EHC — Encompass Health Corporation stock price, charts and financials
QT57Encompass Health CorporationEncompass Health Corporation (NYSE: EHC) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 18.45 | EPS (ttm) | 5.99 | Insider Own | 1.82% | Shs Outstand | 99.20M | Perf Week | -4.77% |
| Market Cap | 10.96B | Forward P/E | 16.90 | EPS next Y | 6.54 | Insider Trans | -10.70% | Shs Float | 97.92M | Perf Month | 3.28% |
| Enterprise Value | 13.55B | PEG | 1.65 | EPS next Q | - | Inst Own | - | Short Float | 4.00% | Perf Quarter | 3.62% |
| Income | 610.00M | P/S | 1.81 | EPS this Y | 0.25% | Inst Trans | - | Short Ratio | 3.90 | Perf Half Y | 17.77% |
| Sales | 6.07B | P/B | 3.26 | EPS next Y | 8.86% | ROA | 8.33% | Short Interest | 3.92M | Perf YTD | 4.11% |
| Book/sh | 33.94 | P/C | 54.54 | EPS next 5Y | 11.19% | ROE | 25.35% | 52W High | 128.00 -13.67% | Perf Year | 1.82% |
| Cash/sh | 2.03 | P/FCF | 23.73 | EPS past 3/5Y | 27.07% 14.22% | ROIC | 13.26% | 52W Low | 92.77 19.11% | Perf 3Y | 67.25% |
| Dividend Est. | 0.84 (0.76%) | EV/EBITDA | 9.27 | Sales past 3/5Y | 10.92% 10.73% | Gross Margin | 58.82% | Volatility | 2.34% 2.49% | Perf 5Y | 71.37% |
| Dividend TTM | 0.76 (0.69%) | EV/Sales | 2.23 | EPS Y/Y TTM | 34.30% | Oper. Margin | 17.93% | ATR (14) | 3.05 | Perf 10Y | 239.27% |
| Dividend Ex-Date | Oct 01, 2026 | Quick Ratio | 1.17 | Sales Y/Y TTM | 12.94% | Profit Margin | 10.04% | RSI (14) | 51.74 | Recom | 2.19 |
| Dividend Gr. 3/5Y | -4.46% -4.71% | Current Ratio | 1.17 | EPS Q/Q | 16.79% | SMA20 | -1.03% | Beta | 0.74 | Target Price | 146.00 |
| Payout | 12.05% | Debt/Eq | 0.83 | Sales Q/Q | 9.07% | SMA50 | 4.11% | Rel Volume | 0.99 | Prev Close | 112.47 |
| Employees | 42,300 | LT Debt/Eq | 0.81 | Earnings | Aug 05 | SMA200 | 3.29% | Avg Volume | 952.30K | Price | 110.50 |
| IPO Date | Sep 24, 1986 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.09% 1.21% | Net Debt/EBITDA | 1.80 | Volume | 940,567 | Change | -1.75% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-22-26 | Reiterated | Leerink Partners | $152 | |
| May-05-26 | Reiterated | Barclays | Overweight | $153 → $140 |
| Feb-06-26 | Reiterated | Barclays | Overweight | $150 → $153 |
| Oct-30-25 | Reiterated | Barclays | Overweight | $101 → $150 |
| Oct-02-25 | Reiterated | UBS | Buy | $110 → $150 |
| Aug-14-25 | Reiterated | Truist Securities | Buy | $140 |
| Apr-28-25 | Reiterated | RBC Capital | Outperform | $105 → $125 |
| Sep-26-24 | Reiterated | RBC Capital | Outperform | $95 → $105 |
| Sep-25-24 | Reiterated | UBS | Buy | $110 |
| May-22-24 | Reiterated | RBC Capital | Outperform | $85 → $95 |
Encompass Health Corporation delivers a range of post-acute healthcare services across the United States, offered both in dedicated facilities and directly within patients' homes. The company's operations are divided into two primary divisions: Inpatient Rehabilitation, and Home Health and Hospice. Its Inpatient Rehabilitation division specializes in providing focused recovery treatment, available on an inpatient or outpatient basis. This care is designed for individuals recuperating from significant health challenges such as strokes, neurological disorders, cardiac and pulmonary issues, brain and spinal cord injuries, complex orthopedic conditions, and amputations. The Home Health and Hospice segment primarily serves the Southeast and Texas regions. Within this segment, home health services encompass a variety of Medicare-certified care options for adult patients, including skilled nursing, medical social work, home health aide assistance, and various therapies like physical, occupational, and speech therapy. Hospice services, on the other hand, provide in-home comfort and support for terminally ill patients and their families. As of June 1, 2022, Encompass Health maintained a substantial network, managing 149 hospitals, 252 home health locations, and 99 hospice locations spread across 42 U.S. states and Puerto Rico. The company, which established its roots in 1983 and is headquartered in Birmingham, Alabama, was formerly known as HealthSouth Corporation until its name change to Encompass Health Corporation in January 2018.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,068 | 5,935 | 5,373 | 4,801 | 4,349 | 4,015 | 3,566 | 4,605 | 4,277 | |
| Cost of Goods Sold Incl. D&A | 2,499 | 254 | 3,140 | 2,818 | 2,595 | 2,312 | 171 | 168 | 159 | |
| Gross Profit | 3,569 | 5,681 | 2,233 | 1,983 | 1,753 | 1,703 | 3,395 | 4,437 | 4,119 | |
| Selling, General and Administrative Excl. Other | 1,072 | 3,411 | 267 | 258 | 209 | 229 | 2,117 | 2,902 | 2,652 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 1,409 | 1,217 | 1,102 | 0 | 914 | 815 | 1,278 | 1,535 | 1,467 | |
| Operating Income | 1,088 | 1,053 | 865 | 1,725 | 630 | 659 | 0 | 693 | 682 | |
| Interest Expense | 123 | 123 | 137 | 144 | 176 | 164 | 184 | 160 | 147 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 39 | 23 | 23 | -974 | -4 | 10 | 537 | 30 | -41 | |
| Net Income Before Taxes | 1,004 | 953 | 750 | 607 | 451 | 505 | 353 | 562 | 493 | |
| Income Taxes | 207 | 193 | 150 | 132 | 100 | 102 | 75 | 116 | 119 | |
| Consolidated Net Income | 610 | 566 | 456 | 352 | 271 | 412 | 284 | 359 | 292 | |
| Net Income From Continuing Operations | 795 | 760 | 599 | 475 | 351 | 403 | 278 | 446 | 374 | |
| Net Income | 610 | 566 | 456 | 352 | 271 | 412 | 284 | 359 | 292 | |
| EPS (Recurring) | 6.08 | 5.62 | 4.53 | 3.54 | 2.72 | 4.15 | 2.87 | 3.65 | 2.99 | |
| EPS (Basic, Before Extraordinaries) | 6.08 | 5.62 | 4.53 | 3.54 | 2.72 | 4.15 | 2.87 | 3.65 | 2.99 | |
| EPS (Diluted) | 5.99 | 5.54 | 4.46 | 3.47 | 2.70 | 4.11 | 2.85 | 3.61 | 2.93 | |
| EBITDA | 1,462 | 1,404 | 1,187 | 1,006 | 870 | 889 | 740 | 941 | 840 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 18.45 | 19.16 | 20.71 | 19.23 | 22.15 | 12.63 | 23.07 | 15.26 | 16.74 | |
| Price To Sales Ratio | 1.80 | 1.81 | 1.72 | 1.39 | 1.36 | 1.28 | 1.83 | 1.17 | 1.12 | |
| Gross Margin | 58.82 | 95.72 | 41.56 | 41.30 | 40.31 | 42.42 | 95.20 | 96.35 | 96.31 | |
| Operating Margin | 17.93 | 17.74 | 16.10 | 35.93 | 14.49 | 16.41 | 0.00 | 15.05 | 15.95 | |
| Net Margin | 10.05 | 9.54 | 8.49 | 7.33 | 6.23 | 10.26 | 7.96 | 7.80 | 6.83 | |
| Shares Outstanding | 99 | 101 | 100 | 100 | 99 | 99 | 99 | 98 | 98 | |
| Market Capitalization | 10,940 | 10,720 | 9,235 | 6,672 | 5,921 | 5,137 | 6,509 | 5,398 | 4,808 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| COLTHARP DOUGLAS E | EVP & Chief Financial Officer | May 15 '26 | Sale | 106.83 | 27,694 | 2,958,550 | 69,377 | May 18 |
| COLTHARP DOUGLAS E | EVP & Chief Financial Officer | May 15 '26 | Option Exercise | 32.94 | 27,694 | 912,240 | 97,071 | May 18 |
| Tuer Patrick William | EVP, Chief Operating Officer | May 11 '26 | Sale | 104.56 | 682 | 71,310 | 24,755 | May 12 |
| Fay Edmund | Sr. Vice Pres. and Treasurer | Mar 09 '26 | Sale | 107.00 | 11,937 | 1,277,259 | 89,325 | Mar 10 |
| Tarr Mark J | President & CEO | Feb 11 '26 | Sale | 111.64 | 150,000 | 16,746,689 | 377,070 | Feb 12 |
| Tuer Patrick William | EVP, Chief Operating Officer | Feb 10 '26 | Sale | 107.62 | 2,804 | 301,766 | 16,042 | Feb 10 |
| Tuer Patrick William | EVP, Chief Operating Officer | Aug 27 '25 | Sale | 123.59 | 1,020 | 126,062 | 18,846 | Aug 27 |
| Tarr Mark J | President & CEO | May 20 '25 | Option Exercise | 40.10 | 118,384 | 4,747,112 | 645,454 | May 20 |
| Tarr Mark J | President & CEO | May 20 '25 | Sale | 121.53 | 118,384 | 14,387,152 | 527,070 | May 20 |
| Charbonneau Elissa Joy | Chief Medical Officer | May 06 '25 | Sale | 116.61 | 4,279 | 498,974 | 11,958 | May 07 |
| Darby John Patrick | EVP, Gen Counsel & Secretary | Apr 29 '25 | Option Exercise | 35.06 | 10,000 | 350,600 | 89,710 | Apr 30 |
| Darby John Patrick | EVP, Gen Counsel & Secretary | Apr 29 '25 | Sale | 114.79 | 10,000 | 1,147,900 | 79,710 | Apr 30 |
| COLTHARP DOUGLAS E | EVP & Chief Financial Officer | Apr 29 '25 | Option Exercise | 31.51 | 43,575 | 1,372,990 | 103,910 | Apr 30 |
| COLTHARP DOUGLAS E | EVP & Chief Financial Officer | Apr 29 '25 | Sale | 115.15 | 43,575 | 5,017,537 | 60,335 | Apr 30 |
| Price Andrew L | Chief Accounting Officer | Feb 13 '25 | Sale | 98.29 | 5,042 | 495,578 | 69,164 | Feb 13 |